A Double-Blind, Randomized, Placebo-Controlled, Single-Dose Two-Period Crossover Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Spinal Cord Injury.
Phase of Trial: Phase II
Latest Information Update: 19 Aug 2015
At a glance
- Drugs KAI 1678 (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors KAI Pharmaceuticals
- 01 Jun 2010 Official title, actual number of patients (5) and lead trial centre (Trident Clinical Research), lead investigator (Bell G) added as reported by ClinicalTrials.gov.
- 01 Jun 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health record NCT01135108).
- 01 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.